Sign in
Active, not recruitingNo phase

Clinical Study to Evaluate Clinical Outcomes of LuxSmart IOL as Compared With LuxGood IOL

Key facts

Who runs it
Cutting Edge SAS
Where
Austria, Czechia, Germany, Philippines, Singapore, and Spain8 sites in 6 countriesChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
251 people enrolled
Started
21 Jun 2023
Ended
Apr 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Implantation of premium monofocal IOL, LuxSmart (device under investigation)
  • Implantation of monofocal IOL, LuxGood (control device)
Record updated
12 February 2025

Who can take part

Age
22 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 42 criteriaShow less

Who can take part

  • Clinically documented age-related cataracts in both eyes
  • Calculated IOL power performed using an optical biometer is within the range of the study and control IOLs (15D to 28D)
  • Male or female adults aged 22 years or older on the day of first-eye surgery
  • Regular corneal astigmatism ≤ 1.0 D (measured by IOL Master) in both eyes
  • Clear intraocular media other than cataract in both eyes
  • Willing and able to comply to the study requirements
  • Capability to understand and sign an IRB approved informed consent form and privacy authorization
  • Monocular best corrected visual acuity projected to be ≤ 0.18 logMAR (≥ 20/30 in Snellen) after IOL implantation in both eyes
  • Subjects must have discontinued use of contact lenses for at least two weeks (for hard or toric lenses) or 3 days (for soft non-toric contact lenses) prior to the pre-operative examination, and throughout the clinical study
  • Current contact lens wearers must demonstrate a stable refraction (within ±0.5 D for both sphere and cylinder) in each eye, as determined by distance manifest refraction on two consecutive examination dates after discontinuation of contact lens wear

Who cannot take part

  • Previous intraocular or corneal surgery in one or both eyes
  • Complicated surgery expected
  • Active infectious conjunctivitis, keratitis or uveitis in either eye within 30 days prior to surgery
  • Subjects who may be expected to require a combined or other surgical procedure in either eye
  • Concurrent or previous (within 30 days) participation in another drug or device investigation
  • Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal or optic disorders) that are predicted to cause future acuity loss to 20/30 or worse in one or both eyes
  • Ocular surface disease (clinical symptoms) in one or both eyes
  • Chronic or recurrent inflammatory eye diseases
  • Systemic medications that may confound the outcome or increase the risk to the subject in the opinion of the investigator (tamsulosin hydrochloride (Flomax) or other medications with similar side effects (floppy iris syndrome)
  • Subjects with conditions that increase the risk of zonular rupture during cataract extraction procedure that may affect the postoperative centration or tilt of the lens
  • Unsuitable for study participation for any other reason, as determined by Investigator's clinical judgment (reason to be documented on eCRF); In addition to above mentioned in- and exclusion criteria, subjects shall be discontinued when certain conditions are present at the time of surgery, including:
  • inability to fixate IOL in desired position. In such cases, the subject shall be followed until the condition has stabilized
  • Regular corneal astigmatism >1.0 D (measured by IOL Master) in one or both eyes
  • Irregular astigmatism (measured by a topographer) in both eyes
  • Difficulties for cooperation
  • Subjects with AMD suspicious eyes as determined by OCT examination
  • Traumatic cataract in one or both eyes as judged by investigator
  • History or presence of macular edema in one or both eyes
  • Instability of keratometry or biometry measurements; Acceptable maximum standard deviation: AL: ± 150 µm; ACD: ± 150 µm; K1 / K2: ± 0.15 D in both eyes
  • Clinically significant, uncontrolled glaucoma with expected negative impact on Contrast Sensitivity and / or visual acuity outcomes in one or both eyes
  • Pupil abnormalities (non-reactive, tonic, abnormally shaped) in one or both eyes
  • Subjects that cannot achieve a minimum pharmacologic pupilar dilatation of 5 mm in one or both eyes
  • Clinically significant dry eye as determined by the investigator's judgement in one or both eyes
  • Anterior segment pathology that might increase intraoperative risk or compromise IOL stability
  • Diabetic retinopathy
  • Congenital ocular anomalies
  • Pregnant, lactating or, if able to bear children, unwilling to use medically acceptable birth control over the course of the study
  • Subjects who are expected to require retinal laser treatment
  • Patients showing contraindications as listed in the current Instructions for use (IFU)
  • zonular instability
  • need for iris manipulation
  • capsular fibrosis or other opacity; and

Where is this trial?

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a multicentric, prospective, randomised, controlled, post-market clinical follow up (PMCF) study to investigate safety, visual outcomes and contrast sensitivity after bilateral implantation of either LuxSmart IOLs (study group) or LuxGood IOLs (control group).

The 2 groups in the trial

  • IOL implantation experimentalTreatment being tested

    Experimental arm: Premium monofocal intraocular lens LuxSmart

    Treatment: Implantation of premium monofocal IOL, LuxSmart (device under investigation)

  • IOL implantation active comparatorExisting treatment, for comparison

    Comparator arm: Monofocal intraocular lens LuxGood

    Treatment: Implantation of monofocal IOL, LuxGood (control device)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Prospective, Multicenter, Controlled, Randomized, Masked Study to Evaluate the Safety and Performance of LuxSmart IOL as Compared With LuxGood IOL In Subjects Undergoing Cataract Extraction
Record updated
12 February 2025